

ACTwatch
2015 Outlet Surveys in sub-Saharan Africa
Severe malaria treatment availability and provider knowledge

Table 1: Availability of severe malaria treatments, among all screened outlets

	Public Health Facility	Community Health Worker	Private Not For-Profit Facility	ALL Public / Not-For-Profit	Private For-Profit Facility	Pharmacy	Drug Store	General Retailer	Itinerant Drug Vendor	ALL Private
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	%	%	% (95% CI)
Madagascar 2015	N=260	N=1,378	N=20	N=1,658	N=330	N=73	N=224	N=11,196	N=0	N=11,823
Artesunate IV/IM	12.7 (7.4, 20.8)	0.0 -	1.0 (0.1, 7.9)	1.6 (0.9, 2.7)	0.1 (0.0, 0.4)	0.0 -	0.0 -	0.0 -	-	0.0 -
Artesunate suppository	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
Artemether IV/IM	0.1 (0.0, 0.6)	0.0 -	0.0 -	0.0 (0.0, 0.1)	0.0 -	1.8 (0.6, 5.2)	0.0 -	0.0 -	-	0.0 -
Arteether IV/IM	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
Quinine IV/IM	44.0 (33.9, 54.6)	0.2 (0.1, 0.8)	60.8 (52.9, 68.2)	5.9 (4.3, 8.1)	50.2 (37.2, 63.2)	76.5 (61.3, 87.0)	53.9 (37.6, 69.3)	0.1 (0.0, 0.4)	-	2.9 (2.3, 3.7)
Nigeria 2015	N=212	N=13	N=15	N=240	N=336	N= 231	N= 2,810	N= 9,799	N= 64	N= 13,240
Artesunate IV/IM	1.0 (0.3, 2.7)	0.0 -	0.0 -	0.8 (0.3, 2.3)	1.4 (0.6, 3.3)	4.7 (2.2, 9.9)	0.2 (0.1, 0.6)	0.0 -	0.0 -	0.1 (0.1, 0.2)
Artesunate suppository	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
Artemether IV/IM	25.4 (17.0, 36.3)	32.1 (7.0, 74.7)	32.1 (10.0, 66.8)	26.5 (18.1, 37.1)	53.0 (32.6, 72.5)	43.0 (28.4, 59.0)	8.7 (5.6, 13.0)	0.0 -	0.0 -	3.3 (2.6, 4.2)
Arteether IV/IM	1.8 (0.5, 6.2)	0.0 -	4.9 (0.6, 30.4)	1.8 (0.6, 5.3)	1.9 (0.8, 4.3)	13.5 (6.8, 24.9)	1.4 (0.3, 6.7)	0.0 -	0.0 -	0.4 (0.1, 1.3)
Quinine IV/IM	4.6 (2.3, 8.7)	0.0 -	27.0 (7.9, 61.4)	5.1 (2.7, 9.4)	19.3 (8.7, 37.7)	9.7 (4.5, 19.6)	1.2 (0.6, 2.4)	0.0 -	0.0 -	0.8 (0.5, 1.2)
Uganda 2015	N=282	N=5618	N=55	N=5955	N=1023	N=493	N=1967	N=0	N=0	N=3483
Artesunate IV/IM	53.1 (42.8, 63.1)	0.0 -	42.3 (26.4, 59.9)	0.8 (0.6, 1.1)	20.0 (16.1, 24.6)	63.8 (53.65, 72.9)	2.3 (1.0, 5.1)	-	-	7.3 (5.5, 9.8)
Artesunate suppository	30.6 (22.7, 39.9)	0.3 (0.1, 0.6)	8.5 (3.3, 20.2)	0.6 (0.4, 1.0)	1.6 (0.9, 2.6)	5.1 (3.1, 8.4)	0.4 (0.2, 1.0)	-	-	0.7 (0.5, 0.9)
Artemether IV/IM	3.1 (1.0, 9.2)	0.0 -	25.5 (14.6, 40.6)	0.2 (0.1, 0.3)	38.4 (33.1, 44.1)	72.9 (63.3, 80.7)	10.0 (7.6, 13.1)	-	-	17.6 (14.8, 20.8)
Arteether IV/IM	0.0 -	0.0 -	2.1 (0.6, 7.2)	<0.1 (<0.1, 0.1)	2.0 (1.0, 4.0)	5.8 (2.1, 14.8)	0.1 (<0.1, 0.5)	-	-	0.6 (0.3, 1.3)
Quinine IV/IM	24.3 (14.7, 37.4)	0.0 -	71.1 (55.6, 82.8)	0.7 (0.5, 1.0)	67.1 (60.2, 73.4)	79.5 (70.1, 86.5)	20.0 (16.5, 24.0)	-	-	31.9 (28.4, 35.6)

Table 1: Availability of severe malaria treatments, among all screened outlets

	Public Health Facility	Community Health Worker	Private Not For-Profit Facility	ALL Public / Not-For-Profit	Private For-Profit Facility	Pharmacy	Drug Store	General Retailer	Itinerant Drug Vendor	ALL Private
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	%	%	% (95% CI)
DRC - Kinshasa	N=205	N=12	N=79	N=296	N=237	N=61	N=574	N=0	N=0	N=872
Artesunate IV/IM	17.9 (10.4, 29.1)	0.0 -	12.8 (5.1, 28.3)	13.1 (7.1, 22.9)	9.6 (6.1, 14.9)	37.4 (27.1, 48.9)	17.8 (15.0, 21.1)	-	-	15.8 (12.9, 19.3)
Artesunate suppository	0.3 (<0.1, 2.2)	0.0 -	0.0 -	0.1 (<0.1, 0.8)	1.9 (0.6, 6.4)	9.5 (2.8, 27.8)	1.7 (0.8, 3.8)	-	-	1.9 (1.0, 3.5)
Artemether IV/IM	9.4 (4.9, 17.2)	0.0 -	6.2 (2.6, 13.9)	6.6 (3.3, 13.0)	5.5 (3.1, 9.8)	43.3 (32.1, 55.3)	30.7 (26.3, 35.6)	-	-	23.9 (20.9, 27.3)
Arteether IV/IM	31.9 (23.9, 41.2)	0.0 -	34.1 (20.2, 51.4)	29.0 (21.0, 38.6)	28.0 (21.6, 35.5)	86.8 (80.5, 91.4)	79.8 (75.3, 83.6)	-	-	65.5 (61.0, 69.8)
Quinine IV/IM	45.4 (35.6, 55.5)	0.0 -	25.2 (13.9, 41.3)	29.6 (22.3, 38.1)	26.2 (17.7, 37.0)	27.4 (17.2, 40.7)	23.2 (16.3, 31.9)	-	-	24.1 (17.9, 31.6)
DRC - Katanga	N=266	N=35	N=23	N=324	N=152	N=8	N=568	N=0	N=0	N=728
Artesunate IV/IM	14.0 (8.5, 22.1)	0.0 -	8.8 (3.0, 23.0)	9.9 (5.6, 17.0)	3.9 (1.5, 9.8)	0.0 -	4.2 (2.6, 6.8)	-	-	4.1 (2.6, 6.4)
Artesunate suppository	6.0 (3.0, 11.6)	18.4 (9.9, 31.4)	2.3 (0.4, 13.0)	9.0 (5.0, 15.6)	0.9 (0.1, 6.2)	0.0 -	0.9 (0.4, 2.0)	-	-	0.9 (0.4, 1.9)
Artemether IV/IM	2.0 (1.0, 4.0)	0.0 -	9.1 (1.3, 43.0)	2.0 (0.9, 4.8)	6.3 (2.9, 13.2)	0.0 -	18.8 (13.1, 26.3)	-	-	15.8 (11.2, 21.8)
Arteether IV/IM	7.4 (4.7, 11.4)	0.0 -	19.3 (5.8, 48.2)	6.4 (3.8, 10.7)	13.8 (9.1, 20.3)	62.5 (62.5, 62.5)	33.7 (25.2, 43.4)	-	-	30.1 (22.1, 39.5)
Quinine IV/IM	55.3 (46.7, 63.7)	0.0 -	72.4 (48.0, 88.2)	42.2 (28.1, 57.6)	46.6 (35.4, 58.2)	50.0 (50.0, 50.0)	38.8 (32.8, 45.3)	-	-	40.7 (35.8, 45.8)

Table 2: Availability of severe malaria treatments, among outlets with at least one antimalarial in stock on the day of the survey

	Public Health Facility	Community Health Worker	Private Not For-Profit Facility	ALL Public / Not-For-Profit	Private For-Profit Facility	Pharmacy	Drug Store	General Retailer	Itinerant Drug Vendor	ALL Private
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	%	%	% (95% CI)
Madagascar 2015	N=244	N=92	N=16	N=352	N=167	N=72	N=189	N=260	N=0	N=688
Artesunate IV/IM	13.5 (7.9, 22.0)	0.0 -	1.5 (0.2, 10.2)	8.1 (4.5, 14.2)	0.2 (0.1, 0.7)	0.0 -	0.0 -	0.0 -	-	0.0 (0.0, 0.1)
Artesunate suppository	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
Artemether IV/IM	0.1 (0.0, 0.6)	0.0 -	0.0 -	0.1 (0.0, 0.4)	0.0 -	1.8 (0.6, 5.2)	0.0 -	0.0 -	-	0.0 (0.0, 0.1)
Arteether IV/IM	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
Quinine IV/IM	46.9 (36.3, 57.7)	2.6 (0.6, 10.8)	89.4 (63.2, 97.6)	30.8 (22.9, 40.0)	79.9 (65.0, 89.5)	77.0 (61.5, 87.5)	69.3 (57.2, 79.2)	2.3 (0.8, 6.0)	-	33.8 (26.3, 42.2)
Nigeria	N=188	N=6	N=10	N= 204	N=221	N= 225	N= 2,701	N= 96	N= 23	N= 3,266
Artesunate IV/IM	1.1 (0.4, 3.0)	0.0 -	0.0 -	1.0 (0.3, 2.8)	1.9 (0.8, 4.7)	4.8 (2.2, 10.1)	0.2 (0.1, 0.6)	0.0 -	0.0 -	0.5 (0.3, 0.9)
Artesunate suppository	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
Artemether IV/IM	28.4 (18.8, 40.5)	81.2 (38.6, 96.7)	82.1 (47.7, 95.8)	32.6 (22.1, 45.2)	70.7 (49.5, 85.6)	44.0 (29.1, 60.1)	9.0 (5.9, 13.6)	0.7 (0.1, 5.0)	0.0 -	14.6 (11.5, 18.3)
Arteether IV/IM	2.1 (0.6, 6.9)	0.0 -	12.5 (1.6, 55.9)	2.2 (0.7, 6.5)	2.6 (1.1, 6.1)	13.8 (7.0, 25.4)	1.5 (0.3, 6.9)	0.0 -	0.0 -	1.9 (0.6, 5.5)
Quinine IV/IM	5.1 (2.6, 9.8)	0.0 -	69.0 (27.6, 92.9)	6.2 (3.3, 11.6)	25.8 (12.8, 45.1)	9.9 (4.6, 20.1)	1.2 (0.6, 2.5)	0.0 -	0.0 -	3.4 (2.0, 5.6)
Uganda 2015	N=275	N=719	N=53	N=1047	N=956	N=476	N=1849	N=0	N=0	N=3281
Artesunate IV/IM	54.4 (44.0, 64.5)	0.0 -	43.3 (26.8, 61.3)	6.5 (3.5, 11.7)	21.5 (17.1, 26.6)	64.9 (54.7, 73.8)	2.4 (1.1, 5.5)	-	-	7.8 (5.8, 10.4)
Artesunate suppository	31.4 (23.3, 40.8)	2.3 (1.0, 5.6)	8.6 (3.3, 20.6)	5.0 (2.8, 8.7)	1.7 (1.0, 2.8)	5.2 (3.1, 8.6)	0.4 (0.2, 1.1)	-	-	0.8 (0.5, 1.3)
Artemether IV/IM	3.1 (1.0, 9.4)	0.0 -	26.1 (15.0, 41.3)	1.6 (0.8, 3.2)	41.3 (35.6, 47.2)	74.1 (64.8, 81.7)	10.7 (8.1, 14.0)	-	-	18.8 (15.9, 22.2)
Arteether IV/IM	0.0 -	0.0 -	2.2 (0.6, 7.4)	0.1 (<0.1, 0.4)	2.1 (1.0, 4.3)	5.9 (2.2, 15.0)	0.1 (<0.1, 0.5)	-	-	0.6 (0.3, 1.4)
Quinine IV/IM	24.9 (15.1, 38.2)	0.0 -	72.7 (56.7, 84.4)	5.6 (3.0, 10.3)	72.1 (64.9, 78.3)	80.9 (71.6, 87.6)	21.4 (17.7, 25.7)	-	-	34.2 (30.6, 38.0)

Table 2: Availability of severe malaria treatments, among outlets with at least one antimalarial in stock on the day of the survey

	Public Health Facility	Community Health Worker	Private Not For-Profit Facility	ALL Public / Not-For-Profit	Private For-Profit Facility	Pharmacy	Drug Store	General Retailer	Itinerant Drug Vendor	ALL Private
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	%	%	% (95% CI)
DRC - Kinshasa	N=201	N=5	N=63	N=269	N=163	N=61	N=563	N=0	N=0	N=787
Artesunate IV/IM	18.2 (10.6, 29.4)	0.0 -	17.5 (7.1, 37.1)	16.9 (9.2, 29.1)	15.2 (9.5, 23.4)	37.4 (27.1, 48.9)	18.2 (15.4, 21.4)	-	-	18.0 (15.0, 21.3)
Artesunate suppository	0.3 (<0.1, 2.2)	0.0 -	0.0 -	0.2 (<0.1, 1.0)	3.0 (0.9, 9.4)	9.5 (2.8, 27.8)	1.7 (0.8, 3.9)	-	-	2.1 (1.2, 3.9)
Artemether IV/IM	9.5 (5.0, 17.4)	0.0 -	8.5 (3.7, 18.2)	8.5 (4.4, 16.0)	8.7 (4.9, 15.1)	43.3 (32.1, 55.3)	31.4 (26.8, 36.5)	-	-	27.1 (23.7, 30.9)
Arteether IV/IM	32.4 (24.1, 42.1)	0.0 -	46.8 (28.6, 65.9)	37.4 (27.9, 48.1)	44.2 (36.2, 52.5)	86.8 (80.5, 91.4)	81.6 (77.0, 85.4)	-	-	74.2 (70.4, 77.7)
Quinine IV/IM	46.1 (36.2, 56.3)	0.0 -	34.6 (19.7, 53.5)	38.2 (30.2, 46.8)	41.3 (28.8, 55.1)	27.4 (17.2, 40.7)	23.7 (16.8, 32.4)	-	-	27.3 (20.7, 35.2)
DRC - Katanga	N=258	N=34	N=19	N=311	N=121	N=7	N=554	N=0	N=0	N=682
Artesunate IV/IM	14.3 (8.7, 22.5)	0.0 -	9.9 (3.3, 26.4)	10.2 (5.7, 17.5)	5.4 (2.0, 13.5)	0.0 -	4.4 (2.8, 7.0)	-	-	4.5 (2.9, 7.0)
Artesunate suppository	6.2 (3.1, 11.9)	18.7 (10.3, 31.6)	2.6 (0.4, 15.7)	9.2 (5.2, 15.9)	1.3 (0.2, 8.5)	0.0 -	0.9 (0.4, 2.1)	-	-	1.0 (0.4, 2.0)
Artemether IV/IM	2.0 (1.0, 4.1)	0.0 -	10.3 (1.5, 46.6)	2.1 (0.9, 5.0)	8.8 (4.0, 18.2)	0.0 -	19.6 (13.6, 27.3)	-	-	17.4 (12.3, 24.0)
Arteether IV/IM	7.6 (4.8, 11.7)	0.0 -	21.7 (6.4, 53.0)	6.6 (3.8, 11.1)	19.1 (12.9, 27.2)	71.4 (71.4, 71.4)	35.1 (26.4, 45.0)	-	-	33.1 (24.5, 43.0)
Quinine IV/IM	56.5 (47.8, 64.7)	0.0 -	81.7 (52.1, 94.8)	43.3 (28.7, 59.3)	64.7 (52.6, 75.1)	57.1 (57.1, 57.1)	40.5 (34.1, 47.2)	-	-	44.8 (39.2, 50.6)

Table 3: Provider knowledge of severe malaria treatment, among outlets with antimalarials in stock on the day of the survey or within the past 3 months

Percentage of providers who cited artesunate, artemether, or quinine IV/IM as the first-line treatment for severe malaria

	Public Health Facility	Community Health Worker	Private Not For-Profit Facility	ALL Public / Not-For-Profit	Private For-Profit Facility	Pharmacy	Drug Store	General Retailer	Itinerant Drug Vendor	ALL Private
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	%	%	% (95% CI)
Madagascar 2015	N=253	N=165	N=16	N=434	N=182	N=73	N=198	N=314	N=0	N=767
Artesunate IV/IM	14.9 (9.4, 22.8)	0.0 -	1.5 (0.2, 10.4)	7.2 (4.4, 11.4)	0.6 (0.2, 1.7)	0.0 -	0.0 -	0.0 -	-	0.1 (<0.1, 0.2)
Artemether IV/IM	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -	0.0 -
Quinine IV/IM	71.7 (60.3, 80.8)	6.1 (3.2, 11.0)	45.2 (24.9, 67.3)	38.3 (28.2, 49.4)	63.3 (40.7, 81.2)	19.4 (11.5, 30.7)	20.1 (12.1, 31.6)	7.6 (3.1, 17.7)	-	18.9 (26.7)
Nigeria 2015	N=198	N=9	N=10	N=217	N=241	N=224	N=2730	N=104	N=27	N=3326
Artesunate IV/IM	3.7 (1.2, 10.4)	0.0 -	0.0 -	3.3 (1.1, 9.2)	4.4 (1.0, 17.5)	0.8 (0.1, 4.5)	1.2 (0.3, 4.9)	0.5 (0.1, 3.7)	0.0 -	1.4 (0.5, 5.3)
Artemether IV/IM	10.7 (5.7, 19.2)	8.8 (1.0, 46.7)	2.5 (0.3, 17.3)	10.4 (5.7, 18.0)	6.3 (2.2, 16.5)	8.7 (3.9, 18.2)	5.7 (3.1, 10.4)	0.0 -	0.0 -	5.6 (3.3, 9.4)
Quinine IV/IM	4.6 (1.8, 11.3)	2.3 (0.3, 17.7)	39.4 (9.7, 79.6)	5.1 (2.3, 10.9)	11.7 (4.0, 30.0)	0.4 (0.1, 2.0)	1.5 (0.5, 4.1)	0.0 -	0.0 -	2.2 (1.0, 4.5)
Uganda 2015	N=280	N=899	N=53	N=1232	N=961	N=463	N=1904	N=0	N=0	N=3328
Artesunate IV/IM	55.3 (47.4, 63.0)	3.9 (1.0, 13.3)	45.6 (29.0, 63.2)	9.0 (5.0, 15.7)	22.3 (17.6, 27.9)	30.4 (21.1, 41.5)	12.6 (10.3, 15.2)	-	-	15.1 (12.9, 17.4)
Artesunate suppository	0.7 (0.2, 2.7)	2.6 (1.5, 4.5)	0.0 -	2.4 (1.4, 4.1)	0.0 -	0.0 -	0.1 (<0.1, 0.3)	-	-	<0.1 (<0.1, 0.3)
Artemether IV/IM	0.2 (<0.1, 0.6)	0.8 (0.2, 2.6)	2.2 (0.5, 8.9)	0.8 (0.3, 2.3)	2.9 (1.5, 5.5)	2.6 (1.0, 6.5)	2.9 (2.0, 4.1)	-	-	2.9 (2.0, 4.0)
Quinine IV/IM	36.3 (29.3, 44.1)	11.2 (8.5, 14.6)	36.6 (21.4, 55.1)	13.9 (10.6, 18.1)	54.9 (50.9, 58.9)	53.4 (44.3, 62.3)	57.7 (54.2, 61.1)	-	-	57.0 (54.1, 59.8)
DRC – Kinshasa 2015	N=204	N=5	N=66	N=275	N=177	N=60	N=560	N=0	N=0	N=797
Artesunate IV/IM	6.2 (2.9, 12.4)	0.0 -	1.6 (0.4, 5.4)	3.6 (1.8, 7.2)	3.8 (1.8, 7.5)	10.1 (5.8, 16.9)	1.1 (0.4, 2.8)	-	-	1.8 (1.1, 3.0)
Artemether IV/IM	2.3 (0.5, 10.1)	0.0 -	1.9 (0.3, 9.8)	1.9 (0.6, 6.4)	0.0 -	4.3 (0.8, 19.8)	0.5 (0.1, 1.8)	-	-	0.5 (0.2, 1.4)
Quinine IV/IM	64.8 (57.0, 71.9)	52.4 (3.6, 97.0)	47.1 (31.0, 63.9)	55.6 (45.3, 65.5)	54.9 (45.3, 64.2)	39.4 (29.8, 49.9)	24.5 (18.5, 31.7)	-	-	31.4 (25.4, 38.0)

Table 3: Provider knowledge of severe malaria treatment, among outlets with antimalarials in stock on the day of the survey or within the past 3 months

Percentage of providers who cited artesunate, artemether, or quinine IV/IM as the first-line treatment for severe malaria

	Public Health Facility	Community Health Worker	Private Not For-Profit Facility	ALL Public / Not-For-Profit	Private For-Profit Facility	Pharmacy	Drug Store	General Retailer	Itinerant Drug Vendor	ALL Private
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	%	%	% (95% CI)
DRC – Katanga 2015	N=261	N=35	N=20	N=316	N=141	N=7	N=560	N=0	N=0	N=708
Artesunate IV/IM	5.6 (3.1, 10.0)	1.8 (0.2, 12.9)	0.0 -	4.2 (2.3, 7.4)	3.3 (1.0, 9.9)	0.0 -	1.5 (0.8, 2.7)	-	-	1.8 (1.0, 3.2)
Artesunate suppository	0.6 (0.1, 3.1)	0.0 -	0.0 -	0.4 (0.1, 2.1)	0.0 -	0.0 -	0.0 -	-	-	0.0 -
Artemether IV/IM	1.2 (0.2, 6.2)	0.0 -	0.0 -	0.8 (0.1, 4.3)	1.5 (0.4, 4.9)	0.0 -	0.8 (0.3, 2.3)	-	-	0.9 (0.4, 2.0)
Quinine IV/IM	59.7 (51.1, 67.6)	5.0 (0.6, 31.7)	53.4 (29.8, 75.5)	44.6 (31.1, 59.1)	59.0 (48.9, 68.4)	42.9 (42.9, 42.9)	26.3 (20.5, 33.0)	-	-	33.3 (28.0, 39.0)

Brand name and manufacturer information for IV/IM artesunate and rectal artesunate

Brand name, manufacturer, country of manufacture	Audited in survey country & year
IV/IM	
Artesun 30mg Guilin Pharmaceuticals (China)	Uganda 2015
Artesun 60mg Guilin Pharmaceuticals (China)	Madagascar 2015 Uganda 2015 Nigeria 2015 DRC 2015
Artesun 120mg Guilin Pharmaceuticals (China)	Uganda 2015 DRC 2015
AT-160 Arau Pharmaceuticals (India)	DRC 2015
AT-120 Arau Pharmaceuticals (India)	DRC 2015
Artesunat 60mg Pharbaco Central Pharmaceutical (Vietnam)	Nigeria 2015
Artexid 60mg Alisons SPRL (India)	DRC 2015
Falci Care 60mg Swiss Parenterals (India)	Uganda 2015
Jawa Artesunate 60mg Jawa International (India)	Nigeria 2015
Larinate 60mg IPCA Laboratories (India)	Uganda 2015 Nigeria 2015
Larinate 120mg IPCA Laboratories (India)	Uganda 2015
Pauco Artesunate 60mg Kwality Pharmaceuticals (India)	Nigeria 2015
Palunate 60mg (India)	DRC 2015
Rekmal 60 Lincoln Pharmaceuticals (India)	Nigeria 2015
Rekmal 120 Lincoln Pharmaceuticals (India)	Nigeria 2015
Start 60mg Lincoln Pharmaceuticals (India)	DRC 2015
Start 120mg Lincoln Pharmaceuticals (India)	DRC 2015
Suppository	
AT-50 Arau Pharmaceuticals (India)	DRC 2015
Gsunate 50 Bliss GVS Pharmaceuticals (India)	Uganda 2015
Gsunate 200 Bliss GVS Pharmaceuticals (India)	Uganda 2015
Plasmotrim-50 Mepha (Switzerland)	Uganda 2015 DRC 2015

